## **Accepted Manuscript**

Triglyceride-lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Kevin C. Maki, PhD, FNLA, John R. Guyton, MD, FNLA, Carl E. Orringer, MD, FNLA, Ian Hamilton-Craig, MBBS, PhD, Dominik D. Alexander, PhD, MSPH, Michael H. Davidson, MD, FNLA

PII: \$1933-2874(16)30042-3

DOI: 10.1016/j.jacl.2016.03.008

Reference: JACL 915

To appear in: Journal of Clinical Lipidology

Received Date: 22 December 2015

Revised Date: 22 February 2016

Accepted Date: 14 March 2016

Please cite this article as: Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH, Triglyceride-lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia, *Journal of Clinical Lipidology* (2016), doi: 10.1016/j.jacl.2016.03.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## ACCEPTED MANUSCRIPT

Triglyceride-lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Kevin C. Maki, PhD, FNLA<sup>1</sup>; John R. Guyton, MD, FNLA<sup>2</sup>; Carl E. Orringer, MD, FNLA<sup>3</sup>; Ian Hamilton-Craig, MBBS, PhD<sup>4</sup>; Dominik D. Alexander, PhD, MSPH<sup>5</sup>; Michael H. Davidson, MD, FNLA<sup>6</sup>

<sup>1</sup>Midwest Center for Metabolic and Cardiovascular Research/MB Clinical Research, Glen Ellyn, IL

<sup>2</sup>Duke University School of Medicine, Durham, NC

<sup>3</sup>University of Miami Miller School of Medicine, Miami, FL

<sup>4</sup>Griffith and Flinders University Schools of Medicine, Queensland and South Australia,

Australia

<sup>5</sup>EpidStat Institute, Ann Arbor, MI

<sup>6</sup>University of Chicago Pritzker School of Medicine, Chicago, IL, and, when the manuscript was written, AstraZeneca Pharmaceuticals, Wilmington, DE

Corresponding Author:

Kevin C. Maki, PhD, CLS, FNLA

Midwest Center for Metabolic and Cardiovascular Research/MB Clinical Research

489 Taft Avenue, Suite 202

Glen Ellyn, IL 60137

## Download English Version:

## https://daneshyari.com/en/article/5615284

Download Persian Version:

https://daneshyari.com/article/5615284

<u>Daneshyari.com</u>